Connect with us

Press Release

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

Published

3 hours ago

on

SHENZHEN, CHINA – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

 

Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Yijin Hardware Establishes China-Based Hockey Stick Manufacturing for Global Brands

Published

25 minutes ago

on

August 19, 2025

By

Yijin Hardware, an engineering-focused manufacturer specializing in precision CNC machining, sheet metal fabrication, and custom fasteners, with in-house capabilities in design, prototyping, production, and quality assurance, serving industries including automotive, aerospace, medical, and energy, has announced the establishment of a dedicated hockey stick manufacturing operation at its existing facility in Yabian Community, Shajing Street, Baoan District, Shenzhen, China. The development addresses increasing global demand for high-performance sports equipment manufacturing capacity and diversified sourcing options for international brands.

The Shenzhen operation produces hockey sticks for professional, amateur, and recreational markets, integrating advanced composite material processing with precision manufacturing techniques. Situated in a region with established supply chain infrastructure for sports equipment, the facility serves both North American and European brand partners while maintaining scalability for emerging markets.

The manufacturing process combines traditional craftsmanship with automated production methods to ensure consistent quality and performance. This includes the use of precision molds, controlled curing environments, and rigorous inspection protocols for each production batch. By aligning production with the needs of global brands, the operation accommodates a range of design specifications, material compositions, and performance characteristics.

Gavin Yi, CEO of Yijin Hardware, commented on the initiative, “The establishment of the hockey stick manufacturing operation in Shenzhen reflects a strategic approach to expanding production capabilities in sectors where material engineering and precision fabrication are essential. The goal was to create a facility that could meet the technical expectations of international sports equipment brands while ensuring efficiency and quality control throughout the manufacturing process.”

In addition to production capabilities, the facility includes a dedicated quality assurance team to oversee compliance with client specifications and industry standards. This encompasses tensile strength testing, flex rating verification, and finish quality assessments to ensure product consistency before distribution.

The decision to build this capability in Shenzhen followed an evaluation of logistical advantages, raw material accessibility, and skilled labor availability. Proximity to established composite material suppliers and streamlined export processes reduces lead times and supports flexible order volumes for brand partners.

Hockey equipment manufacturing has traditionally been concentrated in select regions, but increasing demand for both performance-grade and entry-level sticks has prompted brands to diversify production locations. The Yijin Hardware operation contributes to this diversification by providing a manufacturing base capable of serving multiple market segments without compromising technical requirements.

The move also aligns with a broader shift toward integrated manufacturing solutions, where companies seek partners that can manage design, prototyping, and production under a single operational framework. Leveraging its existing precision engineering expertise, Yijin Hardware adapts manufacturing processes to meet the specific performance metrics required by each client.

Looking toward future developments, Gavin Yi stated, “The hockey stick manufacturing initiative is part of a larger strategy to expand capabilities into new product categories that align with the company’s engineering strengths. Ongoing research and process refinement will focus on improving material performance, optimizing production efficiency, and supporting brand partners in meeting evolving market demands.”

The Shenzhen facility is currently fulfilling orders for multiple international brands, with production schedules structured to meet both seasonal demand and long-term supply agreements. Early collaboration with brand partners included prototype evaluations and design refinements to align output with performance expectations.

For more details regarding hockey stick manufacturers China, Yijin Hardware may be contacted at +1 626 263 5841 or yijing@yijinsolution.com. The company is located at 760 NW 10th Ave, Homestead, FL 33030, USA.

About Yijin Hardware

Yijin Hardware is a leading engineering-focused manufacturer specializing in precision CNC machining, sheet metal fabrication, and custom fasteners. With in-house capabilities in design, prototyping, production, and quality assurance, Yijin Hardware serves diverse industries, including automotive, aerospace, medical, and energy. Known for its commitment to delivering high-quality products, the company supports global brands with innovative manufacturing solutions tailored to meet the specific needs of each sector. Yijin Hardware continues to expand its capabilities, focusing on precision engineering and high-performance manufacturing across a broad range of applications.

Media Contact

Organization: Yijin Hardware

Contact Person: Gavin Yi

Website: http://yijinsolution.com/

Email: Send Email

Contact Number: +16262635841

Address:760 NW 10th Ave

City: Homestead

State: FL 33030

Country:United States

Release id:32354

View source version on King Newswire:
Yijin Hardware Establishes China-Based Hockey Stick Manufacturing for Global Brands

This content is provided by a third-party source. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release.

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Adlytica Launches Startup Incubator Offering AI Tools and $200K Funding to Founders

Published

40 minutes ago

on

August 19, 2025

By

Adlytica introduces its Startup Incubator, providing $30K in AI tools, $200K+ in funding access, mentorship, and lifetime support. With only 5 founders accepted monthly, the program is designed to help entrepreneurs build scalable businesses.

Warsaw, Poland – August 19, 2025 – Adlytica has launched a new Startup Incubator program that provides entrepreneurs with advanced artificial intelligence (AI) tools, one-on-one mentorship, and access to over $200,000 in potential funding per founder.

 The highly selective incubator accepts only a handful of founders each month, aiming to transform how startups are built in an AI-driven economy.

Selective Program Focused on Quality Over Quantity

Adlytica’s incubator program is distinguished by its small cohort size. Accepting only a select few founders per cohort, this approach allows the Adlytica team to devote extensive resources and personalized support to each startup. “We co-build with our founders,” said Shubham Kishore, CEO of Adlytica. “This isn’t standard mentorship — our team becomes an extension of their team. By keeping cohorts small, we ensure each entrepreneur receives the intensive support needed to build tomorrow’s leading companies.”

This hands-on approach means Adlytica’s experts work closely with participants on product development, growth strategies, and leveraging AI technology. The program’s exclusivity is intended to maximize each startup’s chances of success.

Comprehensive Support Valued at Over $230,000

Founders selected for the Adlytica Startup Incubator gain a suite of benefits and resources valued at more than $230,000, including:

AI Tools & Services: Access to Adlytica’s proprietary AI tools and services (worth approximately $30,000) to accelerate development and marketing.

Funding Access: Introductions to investors, grant programs, and credits totaling over $200,000 in potential funding for each startup.

Mentorship & Expertise: Ongoing expert guidance, including lifetime mentorship and marketing support even after the program concludes.

Community & Networking: Access to a private founder community for peer support and networking, plus warm introductions to industry contacts and investors.

Operational Support: Help with legal and compliance matters, and AI-driven growth and search engine optimization (SEO) automation to scale operations efficiently.

By combining technical resources with funding avenues and experienced mentorship, Adlytica’s incubator provides entrepreneurs with the essential tools and support to go from concept to market-ready business.

Empowering Entrepreneurs in an AI-Driven Era

The launch of the Adlytica Startup Incubator comes as AI advancements reshape industries and the job market. Many professionals and first-time founders are looking to create their own ventures, yet traditional startup programs can be highly competitive, costly, or limited in capacity. Adlytica’s incubator seeks to fill this gap by offering an accessible program with intensive support focused on AI innovation.

“AI is changing the business landscape, and many aspiring founders feel left behind,” Kishore said. “Our incubator is a way to empower entrepreneurs to leverage AI in building new companies, rather than being displaced by it.”

Applications and Availability

Applications for the Adlytica Startup Incubator are now open on a rolling basis via the company’s website. Only five startups are accepted into the program each month, so interested entrepreneurs are encouraged to apply early.

About Adlytica

Adlytica is an AI-powered business solutions provider based in Poland, specializing in AI agent development, automation systems, SEO optimization, and digital transformation services. The company leverages advanced technologies to help businesses accelerate growth and efficiency. In addition to its service offerings, Adlytica supports innovation through its Startup Incubator program, providing entrepreneurs with tools, funding access, and mentorship to build successful ventures in an AI-driven world.

Contact

Shubham Kishore
CEO, Adlytica

LinkedIn -https://www.linkedin.com/company/adlyticadigital
Email: s.k@adlytica.com
Website: www.adlytica.com
Warsaw, Poland

Media Contact

Organization: ADLYTICA

Contact Person: SHUBHAM .K

Website: https://adlytica.com/

Email: Send Email

Address:POLAND

State: poland

Country:Poland

Release id:32610

The post Adlytica Launches Startup Incubator Offering AI Tools and $200K Funding to Founders appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

TSS Home Comfort Reaches 165 Perfect 5-Star Google Reviews Cements Reputation as Best HVAC Company in Boise

Published

2 hours ago

on

August 19, 2025

By

TSS Home Comfort, an established provider of residential heating, cooling, and air purification services in Boise and the Treasure Valley, proudly reaches 165 5-star Google ratings. This achievement reflects the company’s consistent delivery of exceptional service and quality workmanship, earning the trust and confidence of homeowners across the region.

“TSS Home Comfort has built its reputation on trust, quality workmanship, and customer service,” said Steve Miller, President of TSS HVAC Services & TSS Home Comfort. “Every review we receive is a reflection of our team’s dedication to doing the job right the first time. We’re honored to be recognized by so many homeowners, and we will continue to raise the bar for HVAC service in Boise.”

TSS Home Comfort’s sustained 5-star performance underscores its commitment to professionalism, punctuality, and honesty. Every technician is fully licensed, background-checked, and undergoes rigorous annual training to ensure the highest standard of safety, accuracy, and customer care.

TSS Home Comfort’s handpicked technicians are passionate about providing a pleasant, hassle-free experience from start to finish. Arriving promptly in clean uniforms and fully stocked service vehicles, they complete each task efficiently so homeowners can return to their day with minimal disruption.

The company’s upfront, straightforward pricing and policy of never recommending unnecessary services set it apart in the HVAC industry. Customers can expect only the solutions they truly need, backed by the team’s decades of expertise.

Comprehensive Services & Local Reach

Serving Boise and the Treasure Valley, TSS Home Comfort provides heating, cooling, and air purification solutions, including:

  • HVAC Installation & Replacement – Energy-efficient systems for year-round comfort
  • Repairs & Emergency Service – 7 days a week across the Treasure Valley
  • Total Care Club Maintenance Plan – Maximizing system performance and lifespan
  • Indoor Air Quality Solutions – Advanced filtration and purification options

Contact TSS Home Comfort

To learn more about TSS Home Comfort or to schedule service, call (208) 908-4330 or visit https://www.tsshomecomfort.com.

TSS Home Comfort
1712 S Roosevelt St, Boise, ID
Phone: (208) 908-4330

About TSS Home Comfort

TSS Home Comfort specializes in heating, cooling, and air purification services for homeowners in Boise and the Treasure Valley. Known for its customer service, professionalism, and transparent pricing, TSS Home Comfort is committed to keeping homes comfortable year-round.

Media Contact

Organization: TSS Home Comfort

Contact Person: Natalie Martin

Website: https://www.tsshomecomfort.com/

Email: Send Email

Contact Number: +12089084330

Address:1712 S Roosevelt St

City: Boise

State: ID

Country:United States

Release id:26035

The post TSS Home Comfort Reaches 165 Perfect 5-Star Google Reviews Cements Reputation as Best HVAC Company in Boise appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us